Anti-Cancer Drugs

The year 2016 witnessed recordable number of US Food and Drug Administration (FDA) approvals of new pharmaceuticals, including new molecular entities (NMEs) and new Biologic License Applications (BLAs). The number was as high as 45 NMEs and BLAs in all disease states compared with 41 approved in 2014 and only 27 in 2013. Out of these 45 NMEs and BLAs entering the market last year, 16 were novel therapies for cancer. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), as many as 836 drugs and vaccines are at various stages of development for cancer; these are either in clinical trials or are awaiting review by the FDA.

 

Of the 836 drugs and vaccines for cancer:

 

  • 123 are for lung cancer (still the leading cause of cancer-related death in the United States)
  • 106 for leukaemia
  • 92 for lymphoma (including non-Hodgkin lymphoma)
  • 82 for breast cancer (the leading cancer in US women)
  • 58 for brain tutors
  • 53 for skin cancer (including melanoma)

  • Alkylating Agents
  • Platinum Analogs
  • Antimetabolites
  • Plant Alkaloids
  • Antitumor Antibiotics
  • Hormonal Agents
  • Differential Inducer
  • Gene Targeted Drugs
  • Immunomodulators
  • Antiangiogenesis Drugs

Related Conference of Anti-Cancer Drugs

October 23-24, 2025

21st Annual Meet on Pharmaceutical Sciences

Paris, France
November 11-12, 2025

6th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
November 13-14, 2025

21st International Conference on Pharmaceutical Chemistry

Aix-en-Provence, France
November 20-21, 2025

21st Annual Congress on Pharmacology and Toxicology

Paris, France
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
December 01-02, 2025

13th International Conference on Clinical Trials

Vancouver, Canada
December 30-31, 2025

40th World Congress on Pharmacology and Therapeutics

Valencia, Spain
February 23-24, 2026

3rd World Congress on Biologics and Biosimilars

London, UK
March 23-24, 2026

36th Annual European Pharma Congress

London, UK
April 16-17, 2026

19th European Biosimilars Congress

Rome, Italy
April 27-28, 2026

9th European Biopharma Congress

Paris, Aland Islands
May 28-29, 2026

3rd International Conference on Pharmacognosy

Madrid, Spain
July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy

Anti-Cancer Drugs Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in